Supercharged immune cells take on advanced melanoma

NCT ID NCT06961357

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a personalized treatment for advanced melanoma using a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL), which are boosted with a protein called CD40L. After a short course of chemotherapy to make room, the enhanced cells are infused back along with interleukin-2. The trial aims to see if this approach can shrink tumors in 36 people who have not responded to standard therapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD40L-augmented tumor infiltrating lymphocytes (TIL)
What this could lead to: If successful, this could offer a new treatment option for advanced melanoma patients who have run out of standard therapies.
What could go wrong: This is an early-phase trial with only 36 participants, so results may not apply broadly. The treatment involves strong chemotherapy and immune side effects are common.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONJUNCTIVAL MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acral lentiginous melanoma cutaneous melanoma iris melanoma malignant conjunctival melanoma melanoma mucosal melanoma uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.